With only two months until the January 1 implementation of the final State Cannabis Regulations, the California agencies given licensing authority under the Medicinal and Adult-use Cannabis Regulation and Safety Act posted last minute changes that are causing quite a buzz in the cannabis community.
Earlier this week, in Potts v. Center for Excellence in Higher Education, the Tenth Circuit held “that the False Claims Act’s anti-retaliation provision unambiguously excludes relief for retaliatory acts occurring after the employee has left employment.” 2018 WL 5796963, — F.3d — (10th Cir. Nov. 6,
On October 26, 2018, the Health Resources and Services Administration (HRSA) updated its online National Practitioner Data Bank (NPDB) Guidebook for the first time since April 2015. The Guidebook provides information to eligible entities and professionals regarding reporting to the NPDB, querying th
Late last month, in Daniels v. Fan Duel, Inc., et ano, the Indiana Supreme Court sided with the fantasy sports industry holding that the use of the names, pictures, and statistics of athletes by online-fantasy sports operators without the athletes’ consent does not violate the right of publicity.
The FDA has delayed the date on which it plans to enforce compliance with certain Unique Device Identification (UDI) requirements, prompting a concerted sigh of relief throughout the medical device community.
As the dust settles on a campaign cycle that was unprecedented in many ways, we have composed this biennial post-election analysis to assist our clients in assessing the potential impact of the elections on their organizations and their industries.
On December 14, 2018, a new bag ordinance in Boston will require all retail stores to stop providing free plastic bags. Given this, retailers in the area should prepare by purchasing appropriate bags and posting a notice at checkout.
Colorado’s new consumer data protection law, the Protections for Consumer Data Privacy Act, took effect September 1 and companies now have another set of requirements to comply with for their data privacy compliance.
The Food and Drug Administration is maintaining its August 2017 commitment to step up enforcement against violative stem cell therapy and regenerative medicine companies. But FDA’s activity hasn’t stopped the Federal Trade Commission from flexing its own regulatory muscle against the same industry.
If the turbulence of 2018 caused business executives grief, the year ahead is unlikely to provide much relief. Foremost is the United States-Mexico-Canada Agreement (USMCA). If most political pundits are correct, the three governments will likely be able to ratify the USMCA in time to be in full fo
The Department of Health and Human Services (HHS) has issued a proposed rule (PR) which would require any television advertisement for a drug or biological covered by Medicare or Medicaid to include a disclosure of the product’s “current list price” for a “typical” thirty day supply.
At Arent Fox, opportunity is a function of creativity, drive, and talent. You won’t find a top-down management structure setting the tone at our firm. Because we’re not a corporation, we’re a partnership. You’re in the driver’s seat. Let’s go.